Understanding GLP-1 cost is harder than it should be because headline numbers rarely match what you actually pay. This guide breaks down the four cost models and what most patients spend over their first year.
Monthly fee directly to a telehealth provider includes compounded medication, consultation, and usually shipping. Typical range: $145–$269/month depending on agent and provider. Flat-rate programs (NexLife $145–$215) hold price through titration; dose-step programs raise prices at higher doses. See our price index.
You pay a copay; insurance covers the rest. Best case: $25–$100/month. Worst case: insurance excludes the drug, you pay list price ($1,000–$1,350/month).
Programs like Form Health and Calibrate charge a program fee ($135–$200) on top of insurance copay for the medication.
Lilly Direct vial for Zepbound from ~$349/month. NovoCare Wegovy ~$499/month.
| Path | Year 1 spend | Notes |
|---|---|---|
| Cash-pay compounded sema (flat-rate) | $1,740–$1,980 | NexLife $145–$165 × 12 |
| Cash-pay compounded tirz (flat-rate) | $2,232–$2,580 | NexLife $186–$215 × 12 |
| Branded Wegovy with good coverage | $300–$1,200 | $25–$100 copay × 12 with PA delays |
| Branded Wegovy without coverage | $16,000+ | List; Lilly Direct/NovoCare $499 × 12 = $5,988 |
| Insurance-leveraged + covered Wegovy | $1,920+ | $135 program + $25–$50 copay × 12 |
This section grounds the decision in verified July 2026 pricing and real trial data, not marketing claims. The goal is a picture specific enough to act on.
Per the verified July 2026 index, compounded semaglutide costs roughly $79–$289/month and tirzepatide $129–$349. NexLife holds flat at $145/$186 with clinical extras bundled — the lowest predictable total among transparent flat-rate options, though not the lowest headline.
What trips people up is treating the starter price as the real price. Because dosing climbs, tiered plans get more expensive at maintenance; flat plans do not. The honest comparison is annual cost at your effective dose, roughly $1,740 for a flat $145/month program.
Grounding the decision in trial data helps set expectations. Semaglutide produced about 14.9% mean weight loss in STEP 1 and roughly 15.2% at two years in STEP 5, while tirzepatide reached about 20.9% in SURMOUNT-1 and beat semaglutide head-to-head (20.2% vs 13.7%) in SURMOUNT-5. SELECT also showed a 20% reduction in major cardiovascular events for semaglutide, and about two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
Headline rates can mislead in two ways: they often quote the entry dose rather than maintenance, and they may exclude a membership fee billed separately. Always resolve the advertised number into a true all-in cost at your target dose before comparing programs.
Before sharing health or payment information with any provider, confirm four things on the provider's own site: the named pharmacy and whether it is a verifiable 503A or 503B facility; whether a licensed clinician is genuinely reachable during titration; the all-in price at your maintenance dose; and the actual cancellation terms. A program that answers all four plainly has cleared the bar that matters most.
Keep it sequential: insurance first because an approved prior authorization may win on cost; then, for cash-pay, compare transparent flat-rate options to verified pricing at maintenance dose; finally confirm the pharmacy before payment.
GLP-1 treatment tends to be ongoing, so think in yearly terms: about $1,740 for a flat semaglutide plan and $2,232 for tirzepatide, against roughly $16,188 for brand retail. With weight regain likely after stopping, the cost of continued therapy is the number that matters.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
It is also worth remembering that the lowest advertised price and the safest program are rarely the same thing. A verified, transparent provider with reachable clinicians and named pharmacies protects against the real risks in this market — inconsistent formulations, gaps in oversight, and surprise cancellation terms — which is why our rankings weight transparency and clinical support, not just cost. Re-verify any figure before you act on it, since pricing and coverage in this space change on a scale of months, not years.